About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Melanoma Clinical Trials in Tennessee | 343 Studies

Clinical Trials MelanomaTennessee

Melanoma Clinical Trials in Tennessee

Find 343 clinical trials for melanoma near Tennessee. Connect with research centers in your area.

All Melanoma trials nationwide All trials in Tennessee

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 121-140 of 343 trials

TerminatedStudy of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) PathwayThis is a multicenter clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers.NCT06287463·Los Angeles, California and 8 others TerminatedStudy of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid TumorsONCR-177-101 is a phase 1, open-label, multi-center, dose escalation and expansion study of ONCR-177, an oncolytic Herpes Simplex Virus for intratumoral injection, alone and in…NCT04348916·Duarte, California and 10 others

Melanoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedNivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or SarcomasThis phase I/II trial studies the side effects and best dose of nivolumab when given with or without ipilimumab to see how well they work in treating younger patients with solid…NCT02304458·Birmingham, Alabama and 24 others

CompletedTreatment for Subjects With Unresectable Stage III or Stage IV MelanomaThis is a randomized, double blind, placebo controlled, multicenter, phase II study to compare the anti-tumor activity as measured by progression-free survival (PFS) and the…NCT00110994·Tucson, Arizona and 13 others

CompletedA Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)The purpose of the study is to estimate the response rate and compare overall survival of patients taking BMS-936558 to those taking study physician's choice of either Dacarbazine…NCT01721746·Phoenix, Arizona and 94 others

CompletedA Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsThis research study is done to test how well different types of cancer respond to the drug called larotrectinib.NCT02576431·Palo Alto, California and 97 others

TerminatedA Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic MelanomaThe primary purpose of this study was to see how tasisulam-sodium affected metastatic melanoma when compared against paclitaxel as measured by overall survival.NCT01006252·Birmingham, Alabama and 121 others

RecruitingStudy of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid TumorsThis study will evaluate the safety, tolerability, and preliminary effectiveness of AMXT 1501 and DFMO when combined with standard treatments for advanced solid tumors.NCT07287917·Tucson, Arizona and 19 others

CompletedStudy Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant RecipientsThe purpose of this study is to determine the effect of sirolimus on the prevention of new non-melanoma skin cancer (NMSC) in kidney transplant recipients.NCT00129961·San Diego, California and 22 others

CompletedInvestigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212This was an open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK2118436 and GSK1120212 in combination.NCT01072175·Los Angeles, California and 14 others

TerminatedA Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their TumorThe purpose of this clinical trial is to evaluate the benefit of the immunotherapeutic product GSK 2132231A in preventing disease relapse when given to melanoma patients, after…NCT00796445·Birmingham, Alabama and 256 others

CompletedAn Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV MelanomaThe purpose of this study is to determine whether an investigational immunotherapy Nivolumab, when combined with Ipilimumab, is more effective than Nivolumab by itself, in…NCT03068455·Tucson, Arizona and 123 others

CompletedA Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic MelanomaThis randomized, open-label, two period crossover study will evaluate the effect of food on the pharmacokinetics of a single dose of RO5185426 and the efficacy and safety of…NCT01264380·La Jolla, California and 9 others

CompletedVaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic MelanomaRATIONALE: Vaccines may make the body build an immune response that will kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells.NCT00003568·Duarte, California and 8 others

TerminatedBRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 MutationsThis open-label, multicenter. single arm Phase I dose-escalation study with efficacy tail extension will evaluate the maximum tolerated dose/recommended dose, the safety and…NCT01519323·Los Angeles, California and 25 others

TerminatedA Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV MelanomaThis is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining a) varlilumab and ipilimumab and b) varlilumab, ipilimumab…NCT02413827·San Francisco, California and 7 others

CompletedStudy to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF InhibitorMEK113583 is a Phase II open-label, multi-site study to investigate the objective response rate, safety, and pharmacokinetics of GSK1120212 in subjects with BRAF mutation-positive…NCT01037127·Los Angeles, California and 9 others

CompletedStudy to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the BrainThis is a multi-cohort, open label, Phase II study with Dabrafenib (GSK2118436) and Trametinib (GSK1120212) combination therapy in subject with BRAF mutation-positive melanoma…NCT02039947·Birmingham, Alabama and 46 others

No longer availableExpanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic MelanomaThe purpose of this study is to provide treatment with nivolumab in combination with ipilimumab to subjects who are anti-(CTLA)-4 and anti-PD-1 treatment-naive and have…NCT02186249·Gilbert, Arizona and 65 others

CompletedAn Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV MelanomaThe purpose of this study is to assess the objective response rate of lenvatinib in previously treated participants with American Joint Committee on Cancer (AJCC) unresectable…NCT01136967·Birmingham, Alabama and 94 others

PreviousPage 7 of 18Next

Other Conditions in Tennessee

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Leukemia Lymphoma